Loading…
Loading…
YI does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for YI and 80,000+ other tickers.
See exactly how YI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for YI and 80,000+ other tickers.
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses…
111, Inc. Announces First Quarter 2026 Unaudited Financial Results PR Newswire SHANGHAI, June 4, 2026
Continuing Transition toward a More Asset-Light and Operationally Efficient Business Model Net Revenue of Promotional Products (1) Increased by 70.2% and Gross Profit Rose by 75.0% Year-over-Year Total Marketplace (MP) Service Revenue Increased by 24.7% Year-over-Year Fulfillment Expenses as a Percentage of Revenue Improved by 10 Basis Points Year-over-Year SHANGHAI, June 4, 2026 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Net revenue amounted to RMB2.4 billion (US$342.4 million), representing a 33.1% decrease from RMB3.5 billion in the prior-year quarter.
Continuing Transition to an Asset-Light Business Model to Improve Overall Efficiency Delivered Non-GAAP Operating Profitability in Both Q4'25 and FY'25 Generated Positive Operating Cash Flow for Both Q4'25 and FY'25 Continued Gross Profit Margin Expansion for B2B Business in Both Q4'25 and FY'25 SHANGHAI, April 9, 2026 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. 2025 Executing Strategic Optimization: Embraces Asset-Light Partnership Network Growth In 2025, the Company proactively implemented strategic structural optimization by divesting its 100% equity interests in several subsidiaries.
Hims and Hers Health (NYSE: HIMS - Get Free Report) and 111 (NASDAQ: YI - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership. Volatility and Risk Hims and Hers Health
Biotricity (OTCMKTS:BTCY - Get Free Report) and 111 (NASDAQ: YI - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a breakdown of recent ratings